← Back to all trials
Completed
NCT05699109
Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients
Conditions: Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia
Sex: All
Ages: 18 Years – 75 Years
Enrollment: 127
Sponsor: Helwan University
Location: Egypt
Summary
This observational study aims to compare long-acting darbepoetin alpha versus short-acting epoetin alpha erythropoietin-stimulating agents in Egyptian hemodialysis patients.
The main questions aim to answer are:What are the effectiveness and safety of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?What is the cost-effectiveness of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?Participants will be divided into 2 groups; epoetin alfa (short-acting ESA), Eprex group, and darbepoetin alfa (long-acting ESA), Aranesp group for six month study period.
Eligibility Criteria
Inclusion Criteria:Patients who have been stable and undergoing hemodialysis three times per week for at least three monthsAge must be 18 or olderPatients who had been receiving a single form of ESA treatment for at least three months before the study's launch.Exclusion Criteria:altered the type of ESA therapy; 2) underwent significant surgery; or (3) received RBC transfusionsfailed to adhere to dialysis therapy, as shown by missing more than two appointments each month.have COVID-19 infection.had cancer.underwent a kidney transplantwere pregnant or nursing motherswere not followed up for the full six-month research period.
Source: ClinicalTrials.gov (NCT05699109). StuddyBuddy aggregates publicly available trial information.
